About lecanemab
Anti-amyloid monoclonal antibody
Used for
- Treats early Alzheimer’s disease, including mild cognitive impairment or mild dementia, with confirmed amyloid plaques.
Usual adult dose
10 mg/kg by intravenous infusion every two weeks initially; after 18 months, maintenance options may include every four weeks.
Common side effects
- Infusion-related reactions
- Headache
- Amyloid-related imaging abnormalities, including brain swelling or bleeding
- Nausea or dizziness
Important warnings
- Can cause serious brain swelling or bleeding; MRI monitoring is required.
- Risk is higher in people with APOE ε4, especially two copies.
- Use caution with anticoagulants or medicines affecting clotting.
- Treatment is for early Alzheimer’s with confirmed amyloid; specialist assessment is needed.
Pregnancy
Human pregnancy data are limited; potential fetal risk is unknown.
Breastfeeding
It is unknown whether lecanemab enters breast milk; effects on infants are uncertain.
Interactions
- Anticoagulants and clot-affecting medicines may increase concern about brain bleeding.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.